New Brunswick Family Medicine · 200 patients
Good evening, Dr. Rivera.
1 trial fits your patients, with 1 pre-screen candidate between them. Ranked by how many of your patients could join. We pre-screened your panel against 39 open trials on Oct 11, 2026; patient records never left your practice.
No candidates in your panel· 6
Open trials where none of your patients pre-screened as a candidate or for chart review, or that haven't been pre-screened yet.
Neuromuscular Disease
Nexiguran ziclumeran
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
- Ages
- 18–85
- Sex
- All
- Enrolling
- 60
- Ends
- Jul 2027
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene
DB-OTO
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat pediatric and adult participants who have severe-to profound and profound hearing loss due to changes in the otoferlin gene. The purpose of this study is to: * Learn about the safety…
- Ages
- Any age
- Sex
- All
- Enrolling
- 36
- Ends
- Feb 2029
Fibrodysplasia Ossificans Progressiva
Garetosmab
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP. For United States: Ages 4 to less than 18 years; for non-US sites only: Ages 2 to less than 18 years. The aim of the study is to see how safe, tolerable,…
- Ages
- 2–18
- Sex
- All
- Enrolling
- 18
- Ends
- Jul 2030
Prion Disease
ALN-6457
This study will test a Regeneron drug called ALN-6457 ("study drug") to see if it can help treat Prion Disease (PrD). In PrD, the prion protein folds into an abnormal shape. These abnormal proteins build up in the brain and cause damage to brain cells, leading to problems with thinking, memory, and movement. ALN-6457…
- Ages
- 18+
- Sex
- All
- Enrolling
- 60
- Ends
- Feb 2031
Amyotrophic Lateral Sclerosis
ALN-SOD
This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be…
- Ages
- 18+
- Sex
- All
- Enrolling
- 54
- Ends
- Mar 2032
Parkinsons Disease
ALN-SNCA
This study is researching an experimental drug called ALN-SNCA (called "study drug"). The study is focused on people with early Parkinson's disease, a disorder of the nervous system that affects movement. Parkinson's disease is caused by a gradual loss of nerve cells in the brain, especially those due to the harmful…
- Ages
- 50–80
- Sex
- All
- Enrolling
- 46
- Ends
- Jun 2029